Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SCN1A | P35498 | 1/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689206 | 0.85 | EPHX2 (0.68) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL2688879 | 0.84 | EPHX2 (0.61) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL3342586 | 0.83 | L3MBTL1 (0.80) | EPHX2MAPTL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL6289577 | 0.82 | L3MBTL1 (0.66) | EPHX2MAPTL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL6833118 | 0.82 | EPHX2 (0.59) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL725251 | 0.81 | EPHX2 (0.63) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL27538195 | 0.81 | EPHX2 (0.63) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL175602 | 0.81 | EPHX2 (0.63) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL19026741 | 0.80 | HDAC4 (0.58) | EPHX2MAPTL3MBTL1HTTTP53 | |
| SCHEMBL22560048 | 0.80 | L3MBTL1 (0.63) | EPHX2MAPTL3MBTL1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815398-B1 | PRE- AND POSTEMERGENCE HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-09 | — | — | US | claimed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | claimed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | claimed |
| EP-1242387-A1 | SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES | Bayer Aktiengesellschaft (DE) | 2002-09-25 | — | — | EP | claimed |
| US-6380430-B1 | ANTICOAGULANTS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTERHAFTUNG (DE) | 2002-04-30 | — | — | US | claimed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | claimed |
| WO-2001034575-A1 | SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-17 | — | — | WO | claimed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-6815398-B1 | PRE- AND POSTEMERGENCE HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-09 | — | — | US | disclosed |
| EP-1458746-A2 | CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5387596-A | Treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4886813-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4052212-A | ETHER-ESTER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1977-10-04 | — | — | US | disclosed |
| US-3971741-A | DISPERSION PIGMENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229236-A1 | Cyclic tetrapeptide compound and use thereof | NGLY1, CRH, NPY1R | EPHX2 3296/4885MAPT 4497/4885L3MBTL1 331/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | EPHX2 2006/4885MAPT 4795/4885L3MBTL1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.